Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.58 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.58 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25223606 | 0.90 | CACNA2D1 (0.49) | CACNA2D1CACNA1BCACNB1GBA1ITGB3 | |
| SCHEMBL25223609 | 0.90 | CACNA2D1 (0.49) | CACNA2D1CACNA1BCACNB1GBA1ITGB3 | |
| SCHEMBL25240030 | 0.90 | CACNA2D1 (0.49) | CACNA2D1CACNA1BCACNB1GBA1ITGB3 | |
| SCHEMBL3825062 | 0.87 | SMN1; SMN2 (0.44) | CACNA2D1CACNA1BCACNB1SMN1; SMN2KDM4E | |
| SCHEMBL1738475 | 0.86 | CACNA2D1 (0.45) | CACNA2D1CACNA1BCACNB1ITGB3ITGA2B | |
| SCHEMBL27140377 | 0.84 | CACNA2D1 (0.45) | CACNA2D1CACNA1BCACNB1ITGB3ITGA2B | |
| SCHEMBL25628610 | 0.84 | CACNA2D1 (0.53) | CACNA2D1CACNA1BCACNB1GBA1SMN1; SMN2 | |
| SCHEMBL4321277 | 0.83 | SMN1; SMN2 (0.54) | CACNA2D1CACNA1BCACNB1SMN1; SMN2KDM4E | |
| SCHEMBL209863 | 0.83 | SMN1; SMN2 (0.50) | CACNA2D1CACNA1BCACNB1SMN1; SMN2KDM4E | |
| SCHEMBL22291286 | 0.83 | ITGB3 (0.46) | CACNA2D1CACNA1BCACNB1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| EP-3947376-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | Astrazeneca AB (SE) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020201080-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA AB (SE) | 2020-10-08 | — | — | WO | disclosed |
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | CACNA2D1 1091/4885CACNA1B 946/4885CACNB1 1474/4885 |
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | CACNA2D1 3809/4885CACNA1B 4683/4885CACNB1 4202/4885 |
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | CACNA2D1 2773/4885CACNA1B 4768/4885CACNB1 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.